Humacyte, Inc. (HUMA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Humacyte, Inc. (HUMA) closed at USD 0.44 on 2026-10-15, a change of -74 % over the past year, with a market capitalization of USD 119.18M.

Humacyte, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Humacyte, Inc. key figures

Previous close

USD 0.44 (2026-10-15)

1-year change

-74 %

Market cap

USD 119.18M

Enterprise value

USD 106.15M

P/E ratio (trailing)

-0.84

P/E ratio (forward)

-1.73

EPS (trailing)

-0.51

EPS (forward)

-0.25

PEG ratio

n/a

Price to book

3.80

Revenue growth

34.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.29

Employees

184

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Humacyte, Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Humacyte, Inc. and compare it with other stocks.